Aytu Biopharma Inc (AYTU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 06/30
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,965 | -13,562 | 6,256 | 2,262 | 1,474 |
| Depreciation Amortization | 832 | 5,485 | 4,165 | 2,821 | 1,361 |
| Accounts receivable | -2,070 | -7,629 | -12,299 | -1,794 | 478 |
| Accounts payable and accrued liabilities | 1,741 | 287 | 1,727 | 1,329 | 3,143 |
| Other Working Capital | -23 | -5,733 | -7,374 | 2,384 | -854 |
| Other Operating Activity | -3,063 | 19,215 | 2,785 | -5,287 | -6,792 |
| Operating Cash Flow | $-618 | $-1,937 | $-4,740 | $1,715 | $-1,190 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | 440 | 457 | 526 | 381 |
| Net Acquisitions | N/A | -3,000 | N/A | N/A | N/A |
| Investing Cash Flow | $N/A | $-2,560 | $457 | $526 | $381 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 5,810 | 6,668 | 7,633 | 1,617 | 1,875 |
| Debt Issued | N/A | 1,857 | N/A | N/A | N/A |
| Debt Repayment | -3,514 | -7,873 | -5,183 | -3,466 | -964 |
| Common Stock Issued | N/A | 14,840 | N/A | N/A | N/A |
| Other Financing Activity | 0 | -49 | 0 | 0 | 0 |
| Financing Cash Flow | $2,296 | $15,443 | $2,450 | $-1,849 | $911 |
| Beginning Cash Position | 30,952 | 20,006 | 20,006 | 20,006 | 20,006 |
| End Cash Position | 32,630 | 30,952 | 18,173 | 20,398 | 20,108 |
| Net Cash Flow | $1,678 | $10,946 | $-1,833 | $392 | $102 |
| Free Cash Flow | |||||
| Operating Cash Flow | -618 | -1,937 | -4,740 | 1,715 | -1,190 |
| Capital Expenditure | N/A | -228 | -211 | -142 | -136 |
| Free Cash Flow | -618 | -2,165 | -4,951 | 1,573 | -1,326 |